Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
2.760
+0.130 (4.94%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Lexeo Therapeutics Stock Forecast
LXEO's stock price has decreased by -67.53% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 10 analysts polled by S&P Global, Lexeo Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $20.3. The average 1-year stock price forecast is 635.51% higher than the current stock price, while the lowest is $9.00 (+226.09%) and the highest is $30 (+986.96%).
Price Target: $20.3 (+635.51%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Lexeo Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 8 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $17 | Buy | Reiterates | $17 | +515.94% | Oct 5, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Reiterates $15 | Buy | Reiterates | $15 | +443.48% | Sep 23, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $20 | Buy | Reiterates | $20 | +624.64% | Sep 23, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $20 | Buy | Maintains | $20 | +624.64% | Aug 13, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $12 → $9 | Buy | Maintains | $12 → $9 | +226.09% | Jun 25, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.20
from -1.93
EPS Next Year
-1.36
from -1.20
EPS and Forward PE are based on non-GAAP adjusted numbers.